ClinicalTrials.Veeva

Menu

Micrometastasis in Gastrointestinal Cancer

University of Oslo (UIO) logo

University of Oslo (UIO)

Status

Unknown

Conditions

Pancreatic Adenocarcinoma
Colorectal Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT01919151
93-08172d6.2008.540

Details and patient eligibility

About

Prognostic and predictive value of assessing the patients micrometastasis status in blood and bone marrow when diagnosed GI cancer. 2 different patient subgroups are currently studied, patients with cancer of the pancreas and patients with liver metastasis secondary to colorectal cancer.

Our hypothesis is that patients with detective circulating tumor cells in the blood or disseminated tumour cells in their bone marrow at diagnosis have a more advanced disease than negative patients. This information may be of therapeutic interest.

Full description

Oncological and overall outcome of the included patients are consecutively registrated at the out-patient clinic. At end of follow-up these survival data are analysed according to the presence of tumor cells in blood and bone marrow, and the prognostic impact of their presence are assessed.

Enrollment

500 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Histological proven adenocarcinoma of the pancreas
  2. Histological/radiological verified colorectal liver metastases
  3. Consent capable patient
  4. Signed written, informed consent

Exclusion criteria

  1. Patient'history of other malignancy

Trial design

500 participants in 1 patient group

Gastrointestinal cancer patients
Description:
Patients with radiological suspected cancer in the pancreas Patients with radiological suspected colorectal liver metastasis

Trial contacts and locations

1

Loading...

Central trial contact

Gro Wiedswang, MD,PhD; Evi Faleide, MD,PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems